科兴制药(688136) - 2021 Q3 - 季度财报

Revenue and Profit - The company's revenue for Q3 2021 was ¥300,801,193.89, representing a decrease of 7.51% compared to the same period last year[5]. - Net profit attributable to shareholders for Q3 2021 was ¥14,561,979.44, down 36.51% year-over-year[5]. - The net profit excluding non-recurring gains and losses for the year-to-date period was ¥65,350,655.97, a decrease of 44.19% compared to the previous year[5]. - Total operating revenue for the first three quarters of 2021 reached ¥896,224,612.15, a slight increase from ¥891,398,225.86 in the same period of 2020, representing a growth of approximately 0.3%[22]. - Net profit for the third quarter of 2021 was ¥75,311,132.71, down from ¥117,483,107.20 in the same quarter of 2020, indicating a decline of approximately 36%[24]. - Earnings per share for the third quarter of 2021 was ¥0.38, compared to ¥0.79 in the same quarter of 2020, showing a decrease of about 52%[25]. Research and Development - Research and development expenses for Q3 2021 totaled ¥33,238,899.27, an increase of 153.95% year-over-year, accounting for 11.05% of revenue[6]. - The company increased its R&D investment significantly, with a year-to-date increase of 78.54% in R&D expenses compared to the previous year[12]. - Research and development expenses for the third quarter of 2021 totaled ¥75,667,529.40, significantly higher than ¥42,380,754.28 in the same quarter of 2020, marking an increase of approximately 78.6%[23]. - The company has ongoing investments in research and development, with a focus on new product development and market expansion strategies[15]. Assets and Liabilities - Total assets as of the end of the reporting period were ¥2,605,624,105.01, reflecting a growth of 10.10% from the end of the previous year[6]. - As of September 30, 2021, total assets amounted to CNY 2.61 billion, an increase from CNY 2.37 billion at the end of 2020[19]. - The total liabilities were CNY 500.67 million, compared to CNY 440.70 million at the end of 2020, indicating an increase in financial obligations[19]. - Total liabilities as of the end of the third quarter of 2021 amounted to ¥716,088,324.79, compared to ¥536,495,748.20 at the end of the previous year, representing an increase of about 33.5%[23]. - The total non-current liabilities amounted to ¥215,421,722.85, compared to ¥95,794,825.78 in the previous year, indicating a significant increase of about 125.5%[23]. - Total liabilities amounted to ¥536,495,748.20, with a year-on-year increase of ¥31,752,978.24[31]. - The company reported a total asset value of ¥2,366,616,447.71, reflecting a slight decrease of ¥31,752,978.24 compared to the previous period[31]. Cash Flow and Financing - Cash inflows from operating activities for the first three quarters of 2021 were ¥942,992,734.12, compared to ¥818,003,174.06 in the same period of 2020, indicating an increase of about 15.3%[26]. - The cash inflow from financing activities was 355,109,057.03 RMB, an increase from 288,716,036.85 RMB in the previous year[27]. - The company paid 243,192,345.52 RMB in debt repayment, which is higher than 204,970,750.03 RMB from the previous year[27]. - The total cash outflow from investing activities was 2,048,263,375.70 RMB, significantly higher than 104,294,355.32 RMB in the same period last year, resulting in a net cash outflow of -574,679,902.47 RMB from investing activities[27]. - The company received cash from investment recovery amounting to 1,396,000,000.00 RMB, indicating strong investment performance[27]. Shareholder Information - The company reported a total of 13,799 common shareholders at the end of the reporting period[13]. - The largest shareholder, Shenzhen Keyi Pharmaceutical Holdings, holds 66.32% of the shares, totaling 131,778,347 shares[13]. Other Financial Metrics - The weighted average return on equity decreased to 0.77%, down 2.08 percentage points year-over-year[6]. - The company reported a tax expense of ¥3,870,689.03 for the third quarter of 2021, down from ¥19,054,484.31 in the same quarter of 2020, representing a decrease of approximately 79.7%[24]. - The company’s retained earnings were reported at ¥352,232,308.28, unchanged from the previous period[31]. - The capital reserve stood at ¥1,266,228,335.40, consistent with prior reporting periods[31]. - The company has not reported any changes in preferred shares or perpetual bonds in the current financial period[31].